HOWL — Werewolf Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-DigitalOcean, Werewolf Therapeutics, Gartner
Werewolf Therapeutics rises on early-stage data for lead drug
Brief: Werewolf Therapeutics Presents Preliminary Monotherapy Data From Phase 1/1b Clinical Trial
U.S. RESEARCH ROUNDUP-Apple, Cabot, Epam Systems
Brief: Werewolf Therapeutics Reports Q1 2023 Financial Results And Provides Business Update
Brief: Werewolf Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results
Brief: Werewolf Therapeutics - On March 16, Entered Into A First Amendment To Amended And Restated Loan And Security Agreement With Pacific Western Bank - Filing
Brief: Werewolf Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Study Of WTX-330
Brief: Werewolf Therapeutics Reports Q3 2022 Results
Brief: Werewolf Therapeutics reports Q2 results
Brief: Werewolf Therapeutics Files For Mixed Shelf Of Up To $150 Million
Brief: Werewolf Therapeutics Reports First Quarter 2022 Financial Results And Provides Business Highlights
U.S. STOCKS ON THE MOVE-Macy's, Conduent, Pfizer
U.S. STOCKS ON THE MOVE-Netflix, Rite Aid, TotalEnergies SE
U.S. STOCKS ON THE MOVE-CDK Global, Sprinklr, Biophytis
Werewolf Therapeutics gains as Jazz buys rights to cancer drug candidate
Brief: Jazz Pharmaceuticals And Werewolf Therapeutics Announce Exclusive Global License And Collaboration Agreement To Develop Wtx-613, A Differentiated, Conditionally-Activated IFNα Indukine Molecule
Brief: Werewolf Therapeutics Reports Fourth Quarter 2021 And Full Year 2021 Financial Results
Brief: Werewolf Added To Nasdaq Biotechnology Index